Isofol Medical: Update on clinical development - DNB

Friday, January 31, 2020 8:31 AM
"Isofol Medical yesterday gave an update on several of its clinical programmes. The AGENT study has randomised 200+ patients and is rapidly approaching interim analysis in Q4 2020e. The company also reported the phase I/IIa study ISC-CC-005 had been concluded and a gene expression analysis method had been validated. We reiterate our SEK18–49 fair value."

Link to commissioned research below.